Since 2001, the Hexacath clinical programme has enrolled thousands of patients internationally and has established the proven efficacy and safety of the Titanium Nitride Oxide coated stents in various population subsets such as Acute Coronary Syndrome patients, small vessels or diabetics. Randomized studies have demonstrated the superiority of this technology versus the first generation DES and its non inferiority versus the most recent DES generations with a trend towards higher safety as soon as 18 months after implantation. At last, Titanium Nitride Oxide Bio Active Stents require only a short term dual anti platelet treatment post stenting.
Case-based presentation: FFR OptoWire and bioactive stent Optimax to m...
TiNOX bio-active technology and its use with respect of current guidel...
Comparison of TItanium-nitride-oxide coated bioactive stent to the Dru...
Catheter-Based Measurements of Absolute Coronary Blood Flow and Microv...
TCT 2017 – TIDES-ACS Trial
Comparison of Titanium-nitride-oxide coated bioactive stent to the Dru...